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Summary  This  paper  describes  a  voluntary  anonymous  survey  to  investigate  the
seroprevalence  of  Hepatitis  C  (HCV)  in  children  in  Glasgow,  UK  attending  a  Dental
Hospital  and  the  proportion  of  HCV  positive  mothers  who  have  a  child  who  is  HCV
seropositive.  The  study  was  undertaken  among  children  and  accompanying  parents
and  household  contacts  attending  a  general  anaesthetic  assessment  clinic  at  Glasgow
Dental  Hospital  and  School.
Children  were  asked  to  provide  an  oral  ﬂuid  specimen  for  HCV  testing.  Accompa-
nying  adults  were  asked  to  provide  demographic  data  on  the  child  and  information  on
familial  risk  factors  for  HCV  infection  using  a  standardised  questionnaire.  Birth  moth-
ers  were  also  asked  to  provide  an  oral  ﬂuid  specimen.  Specimens  and  questionnaires
were  linked  by  a  unique  anonymous  study  number.
Between  June  2009  and  December  2011,  samples  were  collected  from  2141  chil-
dren  and  1698  mothers.  None  of  the  samples  from  the  children  were  HCV  seropositive
but  16  (0.9%,  95%  CI  0.6—1.5%)  of  the  specimens  from  mothers  were  HCV  antibody
positive.
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In  summary,  the  prevalence  of  HCV  seropositivity  in  the  birth  mothers  of  the  children
was  similar  to  that  estimated  in  the  general  population  served  by  the  hospital  and
showed  no  evidence  of  mother-to-child  transmission  of  HCV.
©  2016  King  Saud  Bin  Abdulaziz  University  for  Health  Sciences.  Published  by  Elsevier
Limited.  All  rights  reserved.
Introduction
HCV  is  a  major  public  health  problem  in  Scotland,
with an  estimated  38,000  individuals  chronically
infected with  the  virus  [1]. It is  believed  that
around half  of  those  infected  are  undiagnosed
(approximately  18,000)  and  the  majority  have  a his-
tory of  injecting  drug  use  [2].
A signiﬁcant  number  of  studies  of  the  preva-
lence of  HCV  infection  have  been  completed  in  a
variety of  international  locations,  including  both
endemic  and  non-endemic  areas  [3—20].  There
are few  data  on  the  prevalence  of  HCV  in  chil-
dren and,  with  the  exception  of  a  pilot  study  in
Glasgow  [21],  no  prevalence  surveys  have  been
conducted exclusively  among  children  in  the  UK.
Many of  the  data  on  childhood  prevalence  glob-
ally have  been  derived  from  sub-analyses  of  larger
cross-sectional  surveys  of  the  general  population
[3—5,7—9,12],  though  some  have  focused  on  chil-
dren [6,10,13—20]. There  is  worldwide  geographic
variation in  the  prevalence  of  HCV  infection  in  chil-
dren. With  the  exception  of  surveys  of  children  from
African countries  [8,9,17,18]  the  reported  preva-
lence  of  HCV  in  children  is  usually  very  low  and
frequently less  than  1%  [6,10,13—16,19,20].
Perinatal (vertical)  transmission  is  widely
believed to  be  the  most  common  source  of  HCV
infection in  children  [22]. The  risk  of  transmission
from an  HCV  RNA  positive  mother  at  birth  is
estimated at  5%,  increasing  with  increasing  viral
load, and  almost  entirely  conﬁned  to  those  with
viral loads  of  ≥106/ml  [23—25]. Transmission  has
also been  shown  to  be  associated  with  mater-
nal history  of  injecting  drug  use  [26].  Although
paternal HCV  infection  has  been  reported  as  a
risk factor  for  perinatal  HCV  infection,  it  is  not
an independent  risk  factor,  but  is  dependent  on
maternal  intravenous  drug  use  [26].
There  are  an  estimated  5000  people  who  inject
drugs (PWID)  currently  in  the  NHSGG&C  health
board area  aged  between  15  and  54  years  [27]
and  the  prevalence  of  HCV  in  this  population  has
been reported  as  68%  [28]. While  it  is  anticipated
that children  of  current  and  former  PWIDs  will  be
at  increased  risk  of  HCV  infection,  little  is  known
about the  prevalence  of  HCV  in  children  in  this  geo-
graphical  area.  A  previous  pilot  study  in  Glasgow
[21], which  assessed  the  feasibility  and  accept-
ability  of  recruiting  children  for  an  anonymous
cross-sectional  survey  of  HCV  infection  using  an  oral
ﬂuid collection  device,  reported  a  prevalence  of
2.9% (2/70,  95%  CI:  0.35—9.9),  which  was  higher
than in  the  general  Scottish  population,  where  the
prevalence  is  approximately  1%  [1]. Although  the
sample size  for  the  study  was  small,  the  surpris-
ingly high  prevalence  rate  reported  in  this  study
underscored  the  need  to  investigate  HCV  preva-
lence in  the  paediatric  population  in  Scotland.  The
high prevalence  rate  was  thought  likely  to  reﬂect
the large  population  of  current  and  former  inject-
ing drug  users  who  reside  in  Glasgow  and  the  high
level of  social  deprivation  of  the  population  who
attend the  Dental  Hospital  and  School.
The  primary  objective  of  this  study  was,  there-
fore, to  determine  the  seroprevalence  of  HCV
among  children  in  Glasgow.  Secondary  objectives
were to  determine  the  association  between  mark-
ers of  HCV  infection  in  mothers  and  children,  and  to
identify risk-factors  for  HCV  infection  in  children.
This information  is  important  in  order  to  inform
whether case  ﬁnding  of  children  living  in  house-
holds with  guardians  who  inject  is  required,  and  the
treatment,  care  and  support  needs  for  this  popu-
lation,  which  in  the  USA  have  been  identiﬁed  as
substantial  [29].
Methods
Study design
A  cross-sectional  survey  of  children,  and  when  pos-
sible their  birth  mothers,  resident  in  Glasgow  and
the West  of  Scotland,  recruited  from  the  child
patient population  attending  the  General  Anaes-
thetic  (GA)  Assessment  Clinic  at  the  Glasgow  Dental
Hospital  and  School,  for  assessment  prior  to  dental
extraction.
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Recruitment of participants
Prior  to  each  child’s  attendance  at  the  clinic,  an
invitation  letter  and  information  leaﬂet  was  sent  to
parents/guardians  along  with  the  child’s  appoint-
ment card,  in  order  to  inform  them  of  the  study.
Upon attendance,  a  research  nurse  approached  par-
ents/guardians,  explained  the  study  and  procedure
in detail  and  invited  them  to  provide  informed
written consent  for  the  child  to  participate  in  the
survey. Children  aged  over  seven  years  were  also
asked  to  provide  written  consent  and  children  aged
less than  seven  years  were  asked  to  assent  verbally
to participate.  The  investigator  employed  a vari-
ety of  communication  strategies,  including  play,  to
communicate  with  the  children,  in  particular  pre-
school  children.
Children  were  excluded  from  the  study  if they
were accompanied  by  a  guardian  who  did  not  have
parental  rights  to  consent  for  them  to  participate;
were not  attending  the  clinic  for  assessment;  or
were aged  less  than  3 years  and  more  than  14  years.
Data collection and handling
The  Research  Nurse  interviewed  the  par-
ents/guardians  to  collect  anonymous  demographic
and risk  factor  data  for  HCV  infection  for  the  child
and mothers  using  a  standardised  questionnaire.
Age, gender  and  ethnic  background  of  participants
were recorded,  together  with  post-code  data  to
allow a  deprivation  category  to  be  assigned  to
each participant.  In  addition,  for  each  child,  data
were recorded  on  recognised  risk  factors  for  HCV
infection (blood  transfusion,  organ  transplant,
surgery, tattoos  and  piercings  and  overseas  med-
ical treatment);  co-habitation  with  a  parent  or
other household  member  who  was  a  current  or
former  injecting  drug  user;  co-habitation  with  a
parent or  other  household  member  who  was  HCV
positive;  risk  factors  for  intra-familial  horizontal
transmission (including  sharing  toothbrushes);  risk
factors for  vertical  transmission  (maternal  HCV
infection,  maternal  HCV/HIV  co-infection,  mode
of delivery  at  birth)  and  maternal  country  of  birth.
The maternal  risk  factors  for  infection  collected
were intravenous  drug  use,  history  of  blood  trans-
fusion  or  organ  transplant  and  overseas  medical
treatment. Household  contacts  were  identiﬁed
using the  deﬁnition  used  in  the  2001  Scottish
census, as  ‘‘a  group  of  people  (not  necessarily
related) living  at  the  same  address  with  common
housekeeping, sharing  either  a  living  room  or
sitting  room,  or  at  least  one  meal  a  day’’.
Data  collected  on  those  who  declined  to  partic-
ipate were  the  age  and  gender  of  the  child,  the
relationship  of  the  accompanying  adult  to  the  child
and the  reason  for  non-consent,  to  allow  assess-
ment of  any  response  bias.
Data were  entered  on  a  daily  basis  into  a
password protected  Microsoft  Access  database  on
a secure  password  protected  computer.  Post-code
data were  automatically  converted  to  a social
deprivation category  using  the  Scottish  Index  of
Multiple Deprivation  (SIMD),  then  redacted  on
the questionnaire  and  rendered  unreadable,  in
order to  protect  patient  conﬁdentiality.  All  data
were held  in  accordance  with  the  Caldicott  guide-
lines (http://www.connectingforhealth.nhs.uk/
systemsandservices/infogov/caldicott)
and the  Data  Protection  Act  1998
(http://www.legislation.gov.uk/
ukpga/1998/29/contents).
Saliva specimen collection
Saliva  specimens  were  collected  from  both  chil-
dren and  birth  mothers  using  the  OraSure  collection
device (Epitope  Inc.,  Oregon,  USA).  Participants
were asked  to  insert  the  device  into  their  mouth
between the  lower  cheek  and  gum  and  retain  it
for two  minutes.  Specimens  were  placed  into  a
labelled  vial  and  stored  at −40 ◦C  before  transport
to the  West  of  Scotland  Specialist  Virology  Centre
(WSSVC)  for  testing.  Specimens  from  a child  and
adult were  linked  to  the  questionnaire  data  using  a
unique anonymous  number.
Laboratory testing
Oral  ﬂuid  specimens  were  tested  for  HCV  antibodies
using a modiﬁed  protocol  for  the  Ortho  HCV  3.0  SAVe
ELISA (Product  number  940982,  Ortho  Diagnostics
Amersham). The  sensitivity  and  speciﬁcity  of  this
assay are  92%  and  99%  respectively  [30]  All  reactive
samples were  repeated  using  the  same  assay  and
weakly reactive  samples  were  further  tested  using
modiﬁed  protocols  of  the  recombinant  immunoblot
assay (RIBA).  The  virology  laboratory  held  a  secure
Microsoft  Access  database  containing  the  unique
anonymous  study  number,  date  of  HCV  test,  sample
viability  and  HCV  antibody  test  result,  which  was
merged  on  a  quarterly  basis  with  the  main  study
database.
Data analysis
All  statistical  analyses  were  carried  out  using  SPSS
version 17  and  STATA  version  9.2.  Results  were
presented  as  numbers  and  percentages.  Represen-
tativeness of  the  study  population  was  assessed
using chi-square  test  comparing  the  gender,  age,
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Figure  1  Recruitment  and  hepatitis  C  testing  of  participants  in  the  hepatitis  C  prevalence  survey  of  children  at
Glasgow  Dental  Hospital  and  School,  August  2009  to  December  2011.
ethnicity  and  relationship  with  accompanying  adult
of the  participants  and  non-participants.  HCV
prevalence  is  presented  with  the  95%  conﬁdence
limits (Cl)  calculated  using  the  Wilson  method  for
small n.  Factors  associated  with  maternal  HCV
infection  were  determined  using  univariable  logis-
tic regression  analysis.  Associations  were  expressed
as odds  ratio  (OR)  together  with  their  95%  CI.
Multivariable logistic  regression  analysis  was  not
performed  due  to  the  collinearity  of  the  predictor
variables
Results
Of  the  3111  children  attending  the  General
Anaesthetic  (GA)  Assessment  Clinic  at  Glasgow  Den-
tal  Hospital  and  School  during  the  recruitment
period, 259  did  not  meet  the  inclusion  criteria
and were  excluded.  Of  those  eligible  to  partic-
ipate (n  = 2852),  2141  consented  to  participate
in the  survey  giving  an  overall  participation  rate
of 75%  (Fig.  1). Compared  to  participants,  non-
participants  tended  to  be  younger  (P  ≤  0.001)  and
non-Caucasian  (P  ≤  0.001)  (Table  1).
Of the  2141  children  participating,  1141  (53%)
were  female  and  1333  (62%)  aged  between  3—6
years.  Fifty  nine  percent  of  children  participating
were resident  in  areas  of  Glasgow  considered  to  be
the most  deprived  (SIMD  quintile  4  and  5).  Sixty
seven children  (3.1%)  reportedly  lived  with  some-
one who  had  a  history  of  drug  use;  of  these  31
(46.3%) also  lived  with  someone  who  was  HCV  posi-
tive. One  hundred  and  three  (4.8%)  children  were  of
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Table  1  Comparison  of  characteristics  of  participants  and  non-participants  in  the  eligible  study  population
(n  =  2855).
Characteristic  Non  participantsn =  711%  (n)  Participantsn = 2141%  (n)  p-valuea
Sex
Female  49.6  (353) 46.7  (1000)
Male  50.4  (358) 53.3  (1141) NS
Age-group  (years)
3—6  72.7  (517)  62.3  (1333)
7—10  23.6  (168)  29.8  (638)
11—14  3.6  (26)  7.9  (170)  <0.001
Ethnicity
Caucasian  79.7  (567)  92.0  (1970)
South  Asian  11.0  (78)  4.8  (103)
Other  9.2  (66)  3.2  (68)  <0.001
Relationship  of  accompanying  adult
Mother  83.1  (591)  79.4  (1700)
Father  16.5  (117)  18.4  (395)  0.004
Guardian  lives  with  child  0.4  (3)  2.12  (46)
NS is not signiﬁcant at 5% level.
a Chi-square test.
South  Asian  ethnicity.  Ten  (9.7%)  lived  with,  and  12
(11.6%) had  contact  with,  someone  who  was  HCV
positive.  Twenty  four  children  (1.15%)  were  living
with someone  who  was  HCV  positive  but  did  not
live with  someone  who  had  a  history  of  drug  use  or
were of  South  Asian  ethnicity.  All  children  provided
an oral  ﬂuid  specimen  for  HCV  antibody  testing,  and
zero (0%,  95%  CI  0—0.2%)  were  antibody  positive
Oral ﬂuid  specimens  were  obtained  from  the
majority of  birth  mothers  accompanying  their  chil-
dren (n  =  1698,  99.3%).  Sixteen  birth  mothers  (0.9%,
95% CI  0.6—1.5%)  were  HCV  antibody  positive.
Half of  the  HCV  antibody  positive  mothers  were
aware of  their  HCV  positive  status  at  the  time  of
interview.  Factors  associated  with  maternal  HCV
antibody  were  South  Asia  place  of  birth  (P  = 0.03)
and history  of  injecting  drug  use  (P  <  0.001).  In
addition  to  South  Asia  place  of  birth  (P  = 0.001),
receipt of  medical  treatment  overseas  (P  = 0.007)
was also  associated  with  maternal  HCV  antibody
when mothers  with  a  history  of  injecting  drug  use
were excluded  from  the  analysis  (Table  2).
Discussion
There  are  no  data  on  HCV  infection  in  the  child
population of  the  UK,  although  the  prevalence
is expected  to  be  much  lower  than  in  the  adult
population. In  Scotland,  approximately  0.8%  of
the population  aged  15—59  years  had  been  diag-
nosed  HCV  antibody  positive  by  the  end  of  2014.
The largest  proportion  of  the  diagnosed  individuals
resides in  the  NHS  Greater  Glasgow  and  Clyde  Board
area. Those  at  greatest  risk  of  infection  include  past
and current  people  who  inject  drugs  and  individuals
of South  Asian  origin  [1,31].  It  is  therefore  possible
that children  of infected  women  with  a  history  of
injecting  drugs  will  be  at  the  greatest  risk.  Children
born to  migrants  from  HCV  endemic  areas  may  also
be at  increased  risk.
A  high  proportion  of  children  attending  the
general anaesthetic  assessment  clinic  at  Glasgow
Dental  Hospital  and  School  come  from  areas  of  high
social deprivation.  They  are  more  likely  to  be  from
families  with  a history  of  injecting  drug  use  and
therefore  more  likely  to  have  a  family  member
who is  infected  with  HCV.  While  the  prevalence
of HCV  antibodies  in  participants  from  medium
to low  deprivation  areas  (SIMD  deciles  4—6)  was
as expected  (0.4%),  the  prevalence  among  those
recruited  from  high  deprivation  areas  (SIMD  1—3)
was lower  than  expected  (1.3%  compared  to  an
anticipated  4%).
The  overall  HCV  antibody  prevalence  in  the
mothers recruited  to  this  study  is  consistent  with
the epidemiology  of  HCV  infection  among  the
general population  of  Scotland  [1]. As  expected,
mothers with  a history  of  injecting  drug  use  or  those
of South  Asian  origin  were  signiﬁcantly  more  likely
to be  HCV  antibody  positive.  These  groups  were,
however, under-represented,  with  only  1.5%  and
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Table  2  Factors  associated  with  HCV  Ab  prevalence  among  mothers  of  children  attending  Glasgow  Dental  Hospital,  2009—2011.
Prevalence  of  HCV
antibodies  (all)
Univariate  analysis
all
Prevalence  of  HCV
antibodies
(excluding  PWID)
Univariate  analysisb
excluding  PWID
Total  N n %  of  N 95%  CI OR  95%  CI P Total  N n %  of  N  95%  CI  OR  95%  CI  P
All  1698  16  0.9  0.6  1.5  1684  10  0.6  0.3  1.0
Deprivationa (NR  =  1)
Most  deprived  1026  13  1.3  0.7  2.2  1.0c 1017  10  0.9  0.5  1.8  1.0c
Less  deprived  671  3  0.4  0.2  1.3  0.4  0.1  1.2  0.1  666  0  0.0  0.0  0.5  0.2  0.0  1.3  NS
Maternal  place  of  birth
UK  1608  13  0.8  0.5  1.4  1.0c 1595  7  0.4  0.2  0.9  1.0c
South  Asia  28  2  7.1  2.0  22.6  9.5  2.0  44.0  0.004  28  2  7.1  2.0  22.6  17.5  3.5  88.1  0.001
Other  62  1  1.6  0.3  8.6  4.7  0.3  15.6  NS  61  1  1.6  0.3  8.7  3.8  0.5  31.2  0.221
Previous  blood  transfusion  (NR  =  13)
No  1515  14  0.9  0.6  1.6  1.0c 1504  10  0.7  0.4  1.2  1.0c
Yes 170  2  1.2  0.3  4.2  1.3  0.3  5.7  NS  167  0  0  0  2.2  1.0  0.1  7.9  NS
Overseas  medical  treatment  (NR  =  3)
No  1589  13  0.8  0.5  1.4  1.0c 1577  7  0.4  0.2  0.9  1.0c
Yes 106  3  2.8  1.0  8.2  3.5  1.0  12.6  0.05  104  3  2.9  1.0  8.1  6.7  1.7  26.1  0.007
History  of  injecting  drug  use  (NR  =  16)
No  1684  10  0.6  0.3  1.1  1.0c
Yes  14  6  42.9  21.4  67.8  125.2  36.8  428.5  <0.001
NR = non response.
Bold values signiﬁes statistical signiﬁcance.
a Most deprived = simdquintile 1—3; less deprived = simdquintile 4 & 5.
b Sampling zeros were managed by adding one to each zero cell.
c Baseline.
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0.5%  of  the  ﬁnal  sample  reporting  to  be  of  South
Asian origin  or  providing  a  history  of  injecting  drug
use respectively.  The  prevalence  in  both  groups  was
higher than  that  reported  previously,  but  the  ﬁg-
ures are  based  on  small  numbers  [28,31].  Given  the
small number  of  HCV  positive  mothers  in  the  sam-
ple, it  is perhaps  not  surprising  that  no  HCV  positive
children  were  identiﬁed.  The  prevalence  of  HCV
antibodies  in  this  study  was  lower  than  that  pre-
viously  reported  in  a  small  pilot  study  undertaken
in the  same  clinic  setting  [21].  The  pilot  study  did
not collect  any  demographic  or  risk  information  on
the participants  or  their  mothers,  and  the  reasons
for the  observed  difference  are  unknown.
There  are  a  number  of  possible  explanations  for
the small  proportion  of  mothers  in  the  ﬁnal  sample
with a  recognised  risk  for  HCV  infection.  First,  self-
exclusion  of  mothers  who  had  a  history  of  injecting
drug use  is  likely,  as  32%  of  adults  accompanying
the child  to  the  clinic  indicated  that  the  reason
for non-participation  was  their  unwillingness  to  dis-
close risk  factors;  it  is  not  known  whether  these
individuals were  more  likely  to  be  infected.  Self-
exclusion  of  mothers  who  knew  that  they  or  their
children  were  already  infected  with  HCV  is  also
possible. Second,  non-disclosure  of  a  previous  risk
for HCV  is  also  plausible.  Indeed,  only  half  of  the
HCV antibody  positive  mothers  disclosed  a  recog-
nised  risk  factor(s)  at  the  point  of  recruitment.
Third, the  under-representation  of  those  from  S.
Asia in  the  ﬁnal  sample  may  have  been  a  result  of
fewer children  being  accompanied  by  their  birth
mother  when  compared  with  the  Caucasian  chil-
dren (60%  versus  86%)  or  as  a  consequence  of  a
language  barrier,  though  fewer  than  2%  of  those
eligible to  participate  speciﬁcally  mentioned  this
as a  reason  for  non-participation.  Finally,  the  study
protocol  excluded  any  child  who  attended  with  an
adult who  did  not  have  parental  rights  to  consent  to
the child’s  participation.  Certain  adults  who  are  ‘in
loco parentis’  such  as  foster  parents  or  social  work-
ers may  accompany  children  who  are  more  likely
to come  from  areas  of  deprivation  or  to  have  par-
ents with  a  history  of  drug  use.  Under-recruitment
of such  children  may  have  led  to  an  underestima-
tion of  HCV  prevalence  in  our  child  population.
However,  our  data  indicate  that  only  17  children
were accompanied  by  a  social  worker  or  a foster
carer.
As the  mothers  at  greatest  risk  of  HCV  infec-
tion are  under-represented,  there  is the  possibility
that HCV  antibody  positive  children  may  have  been
missed.  If  we  assume  that  the  participants  are  sim-
ilar in  all  other  respects,  we  might  estimate  (by
applying  the  prevalences  found)  that  we  missed
four HCV  antibody  positive  mothers  who  were  born
outwith  the  UK;  four  HCV  antibody  positive  moth-
ers who  had  received  treatment  outwith  the  UK
(most likely  these  being  the  same  individuals)  and
22 HCV  antibody  positive  mothers  who  had  a  his-
tory of  injecting  drug  use.  Therefore,  overall  there
may have  been  42  HCV  infected  mothers  in  the  pop-
ulation eligible  to  participate.  If  we  assume  75%
chronicity  and  5%  HCV  transmission  rate  we  might
have expected  one  HCV  antibody  positive  child  to
be identiﬁed.
The  strengths  of  this  study  were  our  large  sample
size of  healthy  children  with  paired  maternal  and
child specimens  for  HCV  antibody  testing  linked  to
risk information  for  HCV  infection  from  both  mother
and child.  In  addition,  our  study  was  conducted  in
a clinic  that  treats  a  large  number  of  children  from
areas of  high  level  social  deprivation  that  include
a large  population  of  current  and  former  injecting
drug users.
There  were  three  key  limitations  to  the  study.
First, there  was  the  risk  that  mothers  who  believed
they were  at  risk  of  HCV  infection  chose  not  to
take part.  We  know  this  was  an  issue  in  this  vol-
untary study  and  it is  a  pertinent  reminder  of  the
challenges  of voluntary  surveys  of  children  where
the maternal  risk  can  be  stigmatising  and  fear  of
social care  interventions  can  prevent  participation
and/or disclosure.  Secondly,  while  the  decision  to
collect a  non  invasive  saliva  specimen  was  taken
to encourage  participation  of  children,  the  sen-
sitivity of  the  assay  we  used  was  only  92%  and
we were  unable  to  establish  chronic  infection.
Finally, we  have  assumed  that  the  HCV-seropositive
women were  positive  at  the  time  of  birth  of
the child,  but  this  may  not  have  been  the  case,
since infection  may  have  occurred  after  the  preg-
nancy.
In conclusion,  despite  the  limitations  alluded
to above,  this  study  showed  that  the  prevalence
of HCV  infection  in the  birth  mothers  of  children
attending a General  Anaesthetic  pre-assessment
clinic prior  to  dental  extractions  was  similar  to
the estimate  of  infection  in  the  general  popula-
tion served,  and  showed  no  evidence  of  mother  to
child transmission  in  this  small  group  of  infected
individuals. However,  given  the  introduction  of
highly effective  antiviral  treatment  for  hepatitis
C, resources  should  be  concentrated  on  identifying
and testing  infants  born  to  HCV  infected  women.
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